Genome-wide sequencing studies that identified ZFP36L1 as a driver gene in breast cancer [83] and multiple myeloma [84], identifying inactivating mutations in the ZFP36L1 gene, provided more recent evidence supporting this hypothesis. This evidence concerns the gene ZFP36L1 and AL amyloidosis.